Overview

Gender

male

Marc Beer is a seasoned executive with over 25 years of development and commercialization experience in the biotechnology, pharmaceutical and diagnostic industries.

Most recently, Marc served as Chief Executive Officer and a member of the Board of Directors of Aegerion Pharmaceuticals (NASDAQ: AEGR), where he helped take the company public in October 2010 and played a pivotal role in overseeing the marketing approval of and the successful commercial launch of JUXTAPID (lomitapide), a prescription medicine used by adults with homozygous familial hypercholesterolemia (HoFH) to reduce LDL cholesterol. Prior to Aegerion, Marc was the founding CEO of ViaCell, a biotechnology company specializing in the collection and preservation of umbilical cord blood stem cells, and over a period of 7 years led the company from its inception to a rapidly growing and robust commercial organization. Earlier in his career, Marc held various positions within Genzyme, a specialty care company dedicated to developing treatments for debilitating diseases that are often difficult to diagnose and treat.

Marc holds a B.S. from Miami University (Ohio).